ArticleNature communications2017
Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 75 citations in OpenAlex.
- The Application of Nanomaterials in Breast Cancer.Pharmaceutics · 2025Review
- FROP-1 peptide-conjugated ultrasmall superparamagnetic nanoparticles as a targeted T1-weighted MR contrast agent for breast cancer: in vitro study.BMC biomedical engineering · 2025Article
- Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors toNanomedicine (London, England) · 2025Article
- Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025Review
- Leveraging MRI radiomics signature for predicting the diagnosis of CXCL9 in breast cancer.Heliyon · 2024Article
- MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models.Pharmaceutical research · 2024Article
- MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer.Chemical & biomedical imaging · 2024Article
- Construction of Targeting-Peptide-Based Imaging Reagents and Their Application in Bioimaging.Chemical & biomedical imaging · 2024Review
- A Review on the Design of Carbon-Based Nanomaterials as MRI Contrast Agents.Molecules (Basel, Switzerland) · 2024Review
- Water-soluble endohedral metallofullerenes: new horizons for biomedical applications.Chemical communications (Cambridge, England) · 2023Review
- RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer.Cells · 2023Article
- A pH-responsive TNature communications · 2022Article
- Nanotheranostics for Image-Guided Cancer Treatment.Pharmaceutics · 2022Review
- Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.Pharmaceutical research · 2021Article
- Review
- Article
- Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells.Cells · 2020Article
- Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.Advanced functional materials · 2020Article
- Gadolinium-containing carbon nanomaterials for magnetic resonance imaging: Trends and challenges.Journal of cellular and molecular medicine · 2020Review
- Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.Frontiers in oncology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Molecular imaging of cancer biomarkers is critical for non-invasive accurate cancer detection and risk-stratification in precision healthcare. A peptide-targeted tri-gadolinium nitride metallofullerene, ZD2-Gd
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.